Tags

Type your tag names separated by a space and hit enter

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
J Clin Oncol. 2017 Oct 20; 35(30):3425-3432.JC

Abstract

Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P = .26) and higher in MUD (P = .003), and risk of relapse was lower in both HAPLO (P = .047) and MUD (P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.

Authors+Show Affiliations

Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.Carmen Martínez, Institute of Hematology and Oncology, Hospital Clínic; Carmen Canals, Banc de Sang i Teixits; Anna Sureda, Institut Català d'Oncologia, Hospital Duran i Reynals, Barcelona; Jorge Gayoso, Hospital General Universitario Gregorio Marañón, Madrid; Arancha Bermúdez, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain; Carmen Martínez, Hervé Finel, Silvia Montoto, Peter Dreger, and Anna Sureda, European Society for Blood and Marrow Transplantation, Paris; Didier Blaise, Institut Paoli Calmettes, Marseille; Edouard Forcade, University Hospital of Bordeaux, Bordeaux; Ibrahim Yakoub-Agha, Centre Hospitalier Regional Universitaire de Lille, Lille Inflammation Research International Center, Institut National de la Santé et de la Recherche Médicale U995, Lille, France; Karl Peggs, University College London Cancer Institute; Michael Potter, The Royal Marsden Hospital; Silvia Montoto, St Bartholomew's Hospital, Barts Health National Health Service Trust, London; Stephen Robinson, Bristol Haematology and Oncology Centre, Bristol; Grant McQuaker, Gartnaval General Hospital, Glasgow; Adrian Bloor, Christie National Health Service Trust Hospital, Manchester, United Kingdom; Alida Dominietto, Istituto di Ricovero e Cura a Carattere Scientifico per l'Oncologia, Azienda Ospedaliera-Universitaria San Martino-IST, Genova; Luca Castagna, Istituto Clinico Humanitas; Paolo Corradini, Istituto Nazionale dei Tumori, Milan; Domenico Russo, University of Brescia, Brescia, Italy; Boris Afanasyev, First Pavlov State Medical University of St Petersburg, St Petersburg, Russia; Maija Itälä-Remes, Turku University Hospital, Turku, Finland; Christof Scheid, University of Cologne, Cologne; and Peter Dreger, University of Heidelberg, Heidelberg, Germany.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

28846465

Citation

Martínez, Carmen, et al. "Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: a Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 35, no. 30, 2017, pp. 3425-3432.
Martínez C, Gayoso J, Canals C, et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35(30):3425-3432.
Martínez, C., Gayoso, J., Canals, C., Finel, H., Peggs, K., Dominietto, A., Castagna, L., Afanasyev, B., Robinson, S., Blaise, D., Corradini, P., Itälä-Remes, M., Bermúdez, A., Forcade, E., Russo, D., Potter, M., McQuaker, G., Yakoub-Agha, I., Scheid, C., ... Sureda, A. (2017). Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 35(30), 3425-3432. https://doi.org/10.1200/JCO.2017.72.6869
Martínez C, et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: a Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017 Oct 20;35(30):3425-3432. PubMed PMID: 28846465.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. AU - Martínez,Carmen, AU - Gayoso,Jorge, AU - Canals,Carmen, AU - Finel,Hervé, AU - Peggs,Karl, AU - Dominietto,Alida, AU - Castagna,Luca, AU - Afanasyev,Boris, AU - Robinson,Stephen, AU - Blaise,Didier, AU - Corradini,Paolo, AU - Itälä-Remes,Maija, AU - Bermúdez,Arancha, AU - Forcade,Edouard, AU - Russo,Domenico, AU - Potter,Michael, AU - McQuaker,Grant, AU - Yakoub-Agha,Ibrahim, AU - Scheid,Christof, AU - Bloor,Adrian, AU - Montoto,Silvia, AU - Dreger,Peter, AU - Sureda,Anna, AU - ,, Y1 - 2017/08/28/ PY - 2017/8/29/pubmed PY - 2017/10/31/medline PY - 2017/8/29/entrez SP - 3425 EP - 3432 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 35 IS - 30 N2 - Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO (P = .26) and higher in MUD (P = .003), and risk of relapse was lower in both HAPLO (P = .047) and MUD (P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation. SN - 1527-7755 UR - https://www.unboundmedicine.com/medline/citation/28846465/Post_Transplantation_Cyclophosphamide_Based_Haploidentical_Transplantation_as_Alternative_to_Matched_Sibling_or_Unrelated_Donor_Transplantation_for_Hodgkin_Lymphoma:_A_Registry_Study_of_the_Lymphoma_Working_Party_of_the_European_Society_for_Blood_and_Marrow_Transplantation_ L2 - https://ascopubs.org/doi/10.1200/JCO.2017.72.6869?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -